AI Terminal
ARECOR THERAPEUTICS PLC
AGM Information • Jun 28, 2024
7494_dva_2024-06-28_78bcabb1-cac8-4add-870f-572a1396e318.html
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 4164U
Arecor Therapeutics PLC
28 June 2024
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
RESULT OF AGM
Change of Name of Nominated Adviser and Joint Broker
Cambridge, UK, 28 June 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that at its Annual General Meeting, held today at 12.00 pm, all resolutions were duly passed.
Change of Name of Nominated Adviser and Broker
The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.
-ENDS-
For more information, please contact:
| Arecor Therapeutics plc | www.arecor.com |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Mo Noonan, Communications | Tel: +44 (0) 7876 444977 Email: [email protected] |
| Panmure Liberum Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500 |
| WG Partners LLP (Financial Advisor) Nigel Barnes, Satheesh Nadarajah David Wilson, Claes Spang |
Tel: +44 (0)203 705 9321 |
| Consilium Strategic Communications Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGSEDFDAELSEDM